Table 1. Baseline Characteristics of the Final Study Population.

Characteristic		Total (n = 921)	Development Set (n = 497)	Validation Set (n = 424)	P (Development vs. Validation Sets)
Age, years		31.5 ± 9.0	31.2 ± 8.7	31.9 ± 9.3 0.256
Sex				< 0.001
	Male	624 (67.8)	361 (72.6)	263 (62.0)
	Female	297 (32.2)	136 (27.4)	161 (38.0)
BMI, kg/m2		24.3 ± 3.1	24.3 ± 3.2	24.3 ± 3.2	0.969
AST, IU/mL, median (IQR)		19.0 (16.0, 22.0)	19.0 (16.0, 22.0)	18.0 (16.0, 22.0)	0.741
ALT, IU/mL		20.2 ± 12.3	20.3 ± 12.5	20.1 ± 12.2	0.744
FPG, mg/dL, median (IQR)		92.0 (87.0, 98.0)	91.0 (86.0, 97.0)	65.0 (87.0, 99.0)	0.013
γ-GT, IU/mL, median (IQR)		17.0 (12.0, 26.0)	17.0 (12.0, 26.0)	17.0 (12.0, 26.0)	0.515
TG, mg/dL, median (IQR)		89.0 (62.0, 133.0)	87.0 (61.0, 130.0)	95.0 (64.5, 136.0)	0.096
HDL-C, mg/dL		54.4 ± 13.7	53.8 ± 13.7	55.2 ± 13.7	0.123
CS-MRI-PDFF, %, median (IQR)		2.6 (1.8, 4.7)	2.5 (1.7, 4.5)	2.7 (1.9, 5.0)	0.039
HISTO-MRS-PDFF, %, median (IQR)		2.9 (1.6, 5.3)	2.9 (1.6, 5.1)	2.9 (1.6, 5.4)	0.980
Histologic fat fraction, %		6.5 ± 10.5	6.6 ± 10.9	6.3 ± 10.0	0.590
Hepatic steatosis, %					0.806
	Grade 0 (< 5)	563 (61.1)	309 (62.2)	254 (59.9)
	Grade 1 (5–33)	325 (35.3)	169 (34.0)	156 (36.8)
	Grade 2 (34–66)	30 (3.3)	17 (3.4)	13 (3.1)
	Grade 3 (> 66)	3 (0.3)	2 (0.4)	1 (0.2)

Data are presented as mean ± standard deviation or n (%), unless indicated otherwise. ALT = alanine aminotransferase, AST = aspartate aminotransferase, BMI = body mass index, CS-MRI-PDFF = chemical-shift-imaging-based MRI-proton density fat fraction, FPG = fasting plasma glucose, γ-GT = gamma-glutamyltransferase, HDL-C = high-density lipoprotein cholesterol, HISTO-MRS-PDFF = high-speed T2-corrected multi-echo MR spectroscopy proton density fat fraction, IQR = interquartile range, TG = triglyceride